Pilot Study of the Effects of Intermittent Interleukin‐2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection
Authors:
Open Access
- 1 January 2002
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 185 (1) , 61-8
Abstract
Highly active antiretroviral therapy (HAART) initiated during acute human immunodeficiency virus (HIV) infection may preserve HIV-specific CD4+ T celKeywords
This publication has 32 references indexed in Scilit:
- Immune control of HIV-1 after early treatment of acute infectionNature, 2000
- Discontinuation of Anticytomegalovirus Therapy in Patients With HIV Infection and Cytomegalovirus RetinitisJAMA, 1999
- Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapyNature Medicine, 1999
- Restoration of the immune system with anti-retroviral therapyImmunology Letters, 1999
- Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapyThe Lancet, 1999
- Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapyAmerican Journal of Ophthalmology, 1998
- Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1Nature Medicine, 1998
- Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigensClinical and Experimental Immunology, 1998
- Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 diseaseThe Lancet, 1998
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997